Thomas Hutson, Memorial Sloan Kettering Cancer Center, New York, NY presents A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRCC) vs standard of care at the 2016 annual International Kidney Cancer Symposium.
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRCC) vs standard of care
